Drug – bio-affecting and body treating compositions – Lymphokine
Reexamination Certificate
2009-09-28
2010-10-26
Bunner, Bridget E (Department: 1647)
Drug, bio-affecting and body treating compositions
Lymphokine
C424S094400, C514S002600, C514S404000, C514S469000
Reexamination Certificate
active
07820154
ABSTRACT:
Methods of treating, inhibiting, or ameliorating gout, including chronic acute (refractory) gout, pseudogout, or drug-induced gout, in a human subject in need thereof, comprising administering to a subject in need a therapeutic amount of an interleukin 1 (IL-1) antagonist, wherein the incidence of a gout flare is reduced or inhibited.
REFERENCES:
patent: 6472179 (2002-10-01), Stahl et al.
patent: 6927044 (2005-08-01), Stahl et al.
patent: 2005/0129685 (2005-06-01), Cao et al.
patent: 2005/0197293 (2005-09-01), Mellis et al.
patent: 2007/0161559 (2007-07-01), Petrilli et al.
patent: WO 2004/100987 (2004-11-01), None
patent: WO 2005/117945 (2005-12-01), None
patent: WO 2006/084145 (2006-08-01), None
patent: WO 2007/077042 (2007-07-01), None
patent: WO 2007/077261 (2007-07-01), None
Martinon, 2006, “Gout-associated uric acid crystals activate the NALP3 inflammasome,” Nature 440:237-241 (Nature Publishing Group, London, UK).
Gabay, 2003, “IL-1 Trap,” Curr. Opin. Invest. Drugs 4:593-597 (Thompson Reuters, Philadelphia, PA).
Hashizume et al., 1989, “A role of interleukin-1 (IL-1) in crystal-induced arthritis,” Adv. Exp. Med. Biol. 253a:219-224 (Kluwer Academic/Plenum Publishers, New York, NY).
Takahashi et al., 2003, “Effects of combination treatment using anti-hyperuricaemic agents with fenofibrate and/or losartan . . . ” Ann. Rheum. Dis. 62:572-575 (BMJ, London, UK).
Schlesinger, 2004, “Management of acute and chronic gouty arthritis, present state of the art,” Drugs 64:2399-2416 (Adis Press, Auckland, NZ).
Mellis Scott
Vicary Catherine
Bunner Bridget E
Cottingham Frank R.
Gregg Valeta
Hamud Fozia M
Regeneron Pharmaceuticals Inc.
LandOfFree
Use of IL-1 antagonists to treat gout does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of IL-1 antagonists to treat gout, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of IL-1 antagonists to treat gout will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4166740